Newsroom | 5210 results

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and robust intracranial responses in patients with previously treated extensive stage small cell lung cancer (ES-SCLC) and brain metastases as measured by independent assessment using modified Response Assessment in Neuro-Oncology for Brain Metastases (mRAN...

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, organizzazione globale per la ricerca a contratto (CRO) e società del gruppo JSR Life Sciences, oggi ha annunciato la presentazione di nuovi dati al meeting annuale 2026 dell'AACR, per dimostrare la capacità delle piattaforme integrate e derivate dai pazienti di accelerare lo sviluppo di complesse modalità oncologiche, tra cui gli anticorpi farmaco-coniugati (ADC) e i radiofarmaci. In 12 presentazioni poster, l'azienda punta i riflettori sugli appro...

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, una organización de investigación por contrato (CRO) que opera a nivel global y que forma parte de JSR Life Sciences, anunció hoy que presentará nuevos resultados en el encuentro anual de la AACR 2026 que demuestran cómo las plataformas integradas desarrolladas a partir de muestras de pacientes pueden impulsar el progreso de tratamientos oncológicos complejos, entre los que se incluyen las terapias con conjugados anticuerpo-fármaco (ADC) y radiofárm...

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, een internationale CRO (contract research organization) en een bedrijf van JSR Life Sciences, kondigde vandaag aan dat het nieuwe gegevens zal voorstellen tijdens de AACR Annual Meeting 2026, die aantonen hoe geïntegreerde, patiëntgebaseerde platformen de ontwikkeling van complexe oncologiemodaliteiten kunnen versnellen, met inbegrip van ADC's (antibody-drug conjugates = antilichaam-geneesmiddelconjugaten) en radiofarmaceutica. In 12 posterpresentat...

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, une organisation mondiale de recherche sous contrat (CRO) appartenant à JSR Life Sciences, a annoncé aujourd’hui qu’elle présenterait de nouvelles données lors du Congrès annuel de l’AACR 2026. Ces données démontrent comment les plateformes intégrées dérivées de patients peuvent accélérer le développement de modalités oncologiques complexes, notamment les conjugués anticorps-médicaments (antibody-drug conjugates, ADC) et les produits radiopharmaceut...

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, ein weltweit tätiges Auftragsforschungsunternehmen (Contract Research Organization, CRO) und Unternehmen von JSR Life Sciences, gab heute bekannt dass es bei der Jahrestagung der AACR 2026 neue Daten präsentieren wird, die zeigen, wie integrierte, patientenabgeleitete Plattformen die Entwicklung komplexer onkologischer Modalitäten, einschließlich Antikörper-Arzneistoff-Konjugate (ADCs) und Radiopharmaka, beschleunigen können. Anhand von 12 Postervor...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced an expanded collaboration with DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), to further the innovation, commercialization, and adoption of advanced AI-powered mammography tools. The announcement coincides with the Society of Breast Imaging (SBI) Annual Symposium, where GE HealthCare will showcase its latest advancements in breast imaging and w...

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced it will present new data at the AACR Annual Meeting 2026 demonstrating how integrated, patient-derived platforms can accelerate the development of complex oncology modalities, including antibody-drug conjugates (ADCs) and radiopharmaceuticals. Across 12 poster presentations, the company highlights scalable approaches to improve target selection, optimize p...

ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR) announced today that it will release financial results for first quarter 2026 after market close on Tuesday, April 28, 2026. Following the news release, the company will host a conference call the next day, Wednesday, April 29, 2026, at 10:00 am ET to discuss the results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be availab...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, announced that it will report first quarter 2026 financial results on Thursday, April 30, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast...